103 related articles for article (PubMed ID: 19766386)
21. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
22. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
23. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and treatment of bladder cancer.
Sharma S; Ksheersagar P; Sharma P
Am Fam Physician; 2009 Oct; 80(7):717-23. PubMed ID: 19817342
[TBL] [Abstract][Full Text] [Related]
25. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
[TBL] [Abstract][Full Text] [Related]
26. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
27. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
[TBL] [Abstract][Full Text] [Related]
28. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
29. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
30. Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.
Saito S; Tazaki H; Heston WD; Fair WR
Int J Urol; 1996 Jan; 3(1 Suppl):S35-9. PubMed ID: 24304018
[TBL] [Abstract][Full Text] [Related]
31. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
[TBL] [Abstract][Full Text] [Related]
32. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
33. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
Otto T; Kälble T
Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
[TBL] [Abstract][Full Text] [Related]
34. Superiority of ratio based lymph node staging for bladder cancer.
Herr HW
J Urol; 2003 Mar; 169(3):943-5. PubMed ID: 12576818
[TBL] [Abstract][Full Text] [Related]
35. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
Sweeney P; Millikan R; Donat M; Wood CG; Radtke AS; Pettaway CA; Grossman HB; Dinney CP; Swanson DA; Pisters LL
J Urol; 2003 Jun; 169(6):2113-7. PubMed ID: 12771730
[TBL] [Abstract][Full Text] [Related]
36. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
Wright JL; Lin DW; Porter MP
Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515
[TBL] [Abstract][Full Text] [Related]
37. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
Mills RD; Turner WH; Fleischmann A; Markwalder R; Thalmann GN; Studer UE
J Urol; 2001 Jul; 166(1):19-23. PubMed ID: 11435814
[TBL] [Abstract][Full Text] [Related]
38. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.
Karlsson M; Marits P; Dahl K; Dagöö T; Enerbäck S; Thörn M; Winqvist O
Ann Surg Oncol; 2010 Jul; 17(7):1747-57. PubMed ID: 20119674
[TBL] [Abstract][Full Text] [Related]
39. Transfer of adoptive immunity by intra-arterial injection of tumor-immune pig lymph node cells: treatment of recurrent urinary bladder carcinoma after radical radiotherapy.
Symes MO; Mitchell JP; Eckert H; Roberts JB; Feneley RC; Tribe CR; Lai T
Urology; 1978 Oct; 12(4):398-401. PubMed ID: 715964
[TBL] [Abstract][Full Text] [Related]
40. [Update 2016 - Immunotherapy for urothelial carcinoma].
Retz M; Gschwend JE; Schmid SC
Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
